Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/9201
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Coleções
- IFF - Artigos de Periódicos [1285]
Metadata
Mostrar registro completo
PREVALENCE OF RETINOPATHY OF PREMATURITY IN LATIN AMERICA
Afiliação
Hospital de Clínicas de Porto Alegre. Programa para a Prevenção da Cegueira devido à Retinopatia da prematuridade. Porto Alegre, RS, Brasil.
Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Departamento de Oftalmologia. Faculdade de Medicina. Porto Alegre, RS, Brasil. / Hospital de Clínicas de Porto Alegre. Porto Alegre, RS, Brasil.
Universidade Federal de São Paulo. São Paulo, SP, Brasil.
Fundação Oswlado Cruz. Instituto Fernandes Figueira. Departamento de Neonatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswlado Cruz. Instituto Fernandes Figueira. Departamento de Neonatologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Departamento de Oftalmologia. Faculdade de Medicina. Porto Alegre, RS, Brasil. / Hospital de Clínicas de Porto Alegre. Porto Alegre, RS, Brasil.
Universidade Federal de São Paulo. São Paulo, SP, Brasil.
Fundação Oswlado Cruz. Instituto Fernandes Figueira. Departamento de Neonatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswlado Cruz. Instituto Fernandes Figueira. Departamento de Neonatologia. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
The purpose of this work was to review the studies published over the last 10 years
concerning the prevalence of retinopathy of prematurity (ROP) in Latin American countries, to
determine if there was an improvement in ROP prevalence rates in that period, and to identify
the inclusion criteria for patients at risk of developing ROP in the screening programs. A total
of 33 studies from ten countries published between 2000 and 2010 were reviewed. Prevalence
of any ROP stage in the regions considered ranged from 6.6% to 82%; ROP severe enough to
require treatment ranged from 1.2% to 23.8%. There was no routine screening for ROP, and
there was a lack of services for treatment of the disease in many countries. Inclusion criteria
for patients in the studies ranged between birth weight #1500 g and #2000 g and gestational
age #32 and ,37 weeks. Use of different inclusion criteria regarding birth weight and gestational
age in several Latin American studies hindered comparative analysis of the published data.
Highly restrictive selection criteria for ROP screening in relation to birth weight and gestational
age should not be used throughout most Latin American countries because of their different
social characteristics and variable neonatal care procedures. The studies included in this review
failed to provide adequate information to determine if the prevalence of ROP has decreased in
Latin America.
Compartilhar